Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 5/20 | 0.39 |
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19463531 | 0.83 | SLC18A3 (0.46) | SLC18A3SIGMAR1GAAMAPTTSHR | |
| SCHEMBL242194 | 0.80 | SLC18A3 (0.45) | SLC18A3SIGMAR1GAAMAPTPIM1 | |
| SCHEMBL1366116 | 0.80 | SLC18A3 (0.45) | SLC18A3SIGMAR1GAAMAPTPIM1 | |
| SCHEMBL1367144 | 0.80 | SLC18A3 (0.45) | SLC18A3SIGMAR1GAAMAPTPIM1 | |
| SCHEMBL10513041 | 0.77 | GAA (0.45) | SLC18A3SIGMAR1GAAMAPTTSHR | |
| SCHEMBL2303598 | 0.77 | SLC18A3 (0.42) | SLC18A3SIGMAR1CYP2C19CYP2D6DRD3 | |
| SCHEMBL240786 | 0.77 | SLC18A3 (0.42) | SLC18A3SIGMAR1CYP2C19CYP2D6DRD3 | |
| SCHEMBL2299312 | 0.74 | HTR3A (0.47) | SLC18A3MAPTCYP2C19CYP1A2CYP2D6 | |
| SCHEMBL206905 | 0.74 | SLC18A3 (0.54) | SLC18A3SIGMAR1GAAMAPTTSHR | |
| SCHEMBL11661537 | 0.73 | SLC18A3 (0.52) | SLC18A3SIGMAR1GAAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053434-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-08-21 | — | — | US | claimed |
| EP-3291810-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2018-03-14 | — | — | EP | claimed |
| WO-2016179554-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2016-11-10 | — | — | WO | claimed |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-11-10 | — | — | US | claimed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-107735088-B | Histone deacetylase inhibitors, compositions and methods of use thereof | CHDI基金会股份有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-112566636-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20190202795-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-07-04 | — | — | US | disclosed |
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE HOLDINGS CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10053434-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION | 2011-11-24 | — | — | US | disclosed |
| US-8039471-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| US-7723349-B2 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090124649-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | SLC18A3 4582/4885SIGMAR1 3621/4885GAA 354/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SLC18A3 4422/4885SIGMAR1 1581/4885GAA 223/4885 |
| US-20120115918-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SLC18A3 4422/4885SIGMAR1 1581/4885GAA 223/4885 |
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | MMP9, MMP3, MMP12 | SLC18A3 4582/4885SIGMAR1 3621/4885GAA 354/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SLC18A3 4422/4885SIGMAR1 1581/4885GAA 223/4885 |
| US-20090124649-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | SLC18A3 4582/4885SIGMAR1 3621/4885GAA 354/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SLC18A3 4422/4885SIGMAR1 1581/4885GAA 223/4885 |
| US-20190202795-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | SLC18A3 4635/4885SIGMAR1 4205/4885GAA 100/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SLC18A3 4422/4885SIGMAR1 1581/4885GAA 223/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SLC18A3 4422/4885SIGMAR1 1581/4885GAA 223/4885 |
| US-10053434-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | HDAC1, HDAC7, HDAC5 | SLC18A3 4635/4885SIGMAR1 4205/4885GAA 100/4885 |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | SLC18A3 4635/4885SIGMAR1 4205/4885GAA 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.